Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants with early stage HER2-positive breast cancer
Scheduled to receive neoadjuvant therapy with the objective of conservative surgery
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
You may not be if
Participants with partial or total lobular carcinoma
Participants with inflammatory breast cancer
Previous treatment with chemotherapy, radiation therapy or hormonal therapy for breast cancer
Previous history of cancer (other than curatively treated basal and squamous cell carcinoma of the skin and/or in situ carcinoma of the cervix) relapsing within the 5 years before study entry or in situ contralateral breast carcinoma
Clareo Health | A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
